Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Grip strength

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    114 result(s) found for: Grip strength. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2018-003703-19 Sponsor Protocol Number: 18-002 Start Date*: 2020-04-20
    Sponsor Name:RWTH Aachen University represented by the Rector himself, represented by the Dean of the Medical Faculty
    Full Title: The Effect of Higher Protein Dosing in Critically Ill Patients: A Multicenter Randomized Trial
    Medical condition: Nutritionally high-risk critically ill mechanically ventilated patients. In this sub-study, eligible and enrolled patients randomized to the high protein dose group will achieve its protein goals b...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-003126-42 Sponsor Protocol Number: DT-DEC01-DMD-CT-Phase1/2 Start Date*: 2023-12-12
    Sponsor Name:Dystrogen Therapeutics Technology Polska Spółka z Ograniczoną Odpowiedzialnością
    Full Title: A Phase 1/2, Open-Label, Exploratory Clinical Trial to Evaluate the Safety and Efficacy of DT-DEC01 Therapy in Patients with Duchenne Muscular Dystrophy
    Medical condition: Duchenne muscular dystrophy (DMD) is the most common inherited neuromuscular disease that mostly affects boys. DMD is a type of X-linked disease caused by a mutation of the gene at the Xp21 locus t...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023650-36 Sponsor Protocol Number: HT-ANAM-303 Start Date*: Information not available in EudraCT
    Sponsor Name:Helsinn Therapeutics (U.S.), Inc.
    Full Title: Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer – Cachexia (NSCLC-C): An Extension Study (ROMANA-3)
    Medical condition: Non-Small Cell Lung Cancer related Cachexia (NSCLC-C)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) NL (Completed) GB (Completed) ES (Completed) CZ (Completed) PL (Completed) DE (Completed) IT (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2010-023648-34 Sponsor Protocol Number: HT-ANAM-301 Start Date*: 2011-09-15
    Sponsor Name:Helsinn Therapeutics (U.S.), Inc.
    Full Title: Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer – Cachexia (NSCLC-C): A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Safety and Efficacy ...
    Medical condition: Non-Small Cell Lung Cancer related Cachexia (NSCLC-C)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10002646 Anorexia LLT
    14.1 10027433 - Metabolism and nutrition disorders 10064015 Cancer cachexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) ES (Completed) DE (Completed) CZ (Completed) IT (Completed) SI (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-004903-33 Sponsor Protocol Number: IBM4809 Start Date*: 2018-06-18
    Sponsor Name:Orphazyme A/S
    Full Title: Phase 2/3 Study of Arimoclomol in Inclusion Body Myositis (IBM) A Randomized, Double-blind, Placebo-Controlled Trial
    Medical condition: Sporadic Inclusion Body Myositis (sIBM)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10075052 Sporadic inclusion body myositis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-023649-31 Sponsor Protocol Number: HT-ANAM-302 Start Date*: 2011-07-29
    Sponsor Name:Helsinn Therapeutics (U.S.), Inc.
    Full Title: Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer – Cachexia (NSCLC-C): A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Safety and Efficacy ...
    Medical condition: Non-Small Cell Lung Cancer related Cachexia (NSCLC-C)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10002646 Anorexia LLT
    13.1 10027433 - Metabolism and nutrition disorders 10064015 Cancer cachexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000360-42 Sponsor Protocol Number: UX001-CL302 Start Date*: 2016-08-02
    Sponsor Name:Ultragenyx Pharmaceutical Inc.
    Full Title: A Phase 3b Open-label Extension Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients with GNE Myopathy (GNEM) or Hereditary Inclusion Body Myo...
    Medical condition: GNE Myopathy, also known as Hereditary Inclusion Body Myopathy (HIBM), Distal Myopathy with Rimmed Vacuoles (DMRV), Nonaka's disease, or quadriceps sparing myopathy (QSM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000167584 10075048 Hereditary inclusion body myopathy LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10077945 GNE myopathy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BG (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004988-32 Sponsor Protocol Number: NL46993.078.13 Start Date*: 2014-01-22
    Sponsor Name:Erasmus MC
    Full Title: Rotterdam Observational Study in CIDP of Pharmacokinetics of Intravenous γ-globulin
    Medical condition: Chronic Inflammatory Demyelinating Polyneuropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2004-001666-40 Sponsor Protocol Number: CZOL446H2202E1 Start Date*: 2005-02-01
    Sponsor Name:Novartis Pharma AG
    Full Title: An international, multicenter, randomized, open-label, safety and efficacy trial of intravenous zoledronic acid administered either once or twice yearly in children with severe osteogenesis imperfe...
    Medical condition: Osteogenesis Imperfecta
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003179-16 Sponsor Protocol Number: DA-SARC Start Date*: 2020-11-13
    Sponsor Name:FUNDACIÓ PARC TAULÍ
    Full Title: Randomized Clinical Trial Comparing Arthroscopic Debridement Versus Autologous Cytokine Rich Serum for the Treatment of Lateral Epicondylitis
    Medical condition: Lateral Epicondylitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000832-85 Sponsor Protocol Number: 2013-000832-85 Start Date*: 2013-10-28
    Sponsor Name:Fondazione Salvatore Maugeri, IRCCS
    Full Title: INTRAMUSCULAR CLODRONATE 200 MG IN THE THERAPY OF HANDS IN PHASE ALGIC OSTEOARTHROSIS - A 6 MONTHS PILOT OPEN STUDY.
    Medical condition: Painful osteoarthritis of the hands
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003635-46 Sponsor Protocol Number: 05/MRE10/72 Start Date*: 2006-05-16
    Sponsor Name:NHS Lothian University, Research & Development
    Full Title: Do Anti-Oxidants Modulate the Outcome of Fractures? The Effect of Vitamin C on Functional Outcome Following Fracture of Distal Radius: A Prospective randomised controlled trial.
    Medical condition: Adult patients with fractures of the distal radius.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-003448-28 Sponsor Protocol Number: IgPro20_3003 Start Date*: 2012-04-20
    Sponsor Name:CSL Behring GmbH
    Full Title: Randomized, multicenter, double-blind, placebo-controlled, parallel-group phase III study to investigate the efficacy, safety, and tolerability of 2 different doses of IgPro20 (subcutaneous immunog...
    Medical condition: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10061811 Demyelinating polyneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) ES (Completed) FI (Completed) NL (Completed) AT (Completed) GB (Completed) IT (Completed) BE (Completed) LT (Prematurely Ended) PL (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003134-33 Sponsor Protocol Number: R1033-SRC-1239 Start Date*: 2014-01-31
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF 3-MONTH SUBCUTANEOUS REGN1033 TREATMENT IN PATIENTS WITH SARCOPENIA
    Medical condition: Sarcopenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10063024 Sarcopenia PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-013841-27 Sponsor Protocol Number: 160604 Start Date*: 2009-12-17
    Sponsor Name:Baxter Innovations GmbH
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Cross-over Study of the Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Multofocl Motor Neuropathy
    Medical condition: Multifocal motor neuropathy
    Disease: Version SOC Term Classification Code Term Level
    12.0 10065579 Multifocal motor neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-001431-20 Sponsor Protocol Number: CHDR1417 Start Date*: 2015-08-17
    Sponsor Name:Centre for Human Drug Research
    Full Title: A randomized, double blind, double-dummy placebo controlled, 3-way cross-over study to determine the test-retest reliability of, and the effect of oral retigabine and riluzole on, peripheral motor ...
    Medical condition: Amytrophic Lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-002024-24 Sponsor Protocol Number: AUH-2016-100 Start Date*: 2017-09-08
    Sponsor Name:Aarhus Unversity Hospital
    Full Title: Randomized, cohort study of standardized reduction of subcutaneous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy
    Medical condition: Chronic inflammatory demyelinating polyneuroapthy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000014567 10077384 Chronic inflammatory demyelinating polyneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-001732-21 Sponsor Protocol Number: MET001 Start Date*: 2013-09-06
    Sponsor Name:Centre d'Etude des Cellules Souches (CECS)
    Full Title: A randomized, double blind, placebo-controlled phase II study of metformin in myotonic dystrophy type 1 patients
    Medical condition: Myotonic dystrophy type 1 (DM1) also known as Steinert disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-001428-20 Sponsor Protocol Number: 2012-100 Start Date*: 2013-06-06
    Sponsor Name:Aarhus University Hospital
    Full Title: Randomized, single-blind crossover study of subcutaneous immunoglobulin in newly diagnosed patients with chronic inflammatory demyelinating polyradiculoneuropathy
    Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029205 - Nervous system disorders 10064135 Polyneuropathy chronic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001543-13 Sponsor Protocol Number: HIP-SAP Start Date*: 2018-03-28
    Sponsor Name:Morten Tange Kristensen/Hvidovre Hospital
    Full Title: Preliminary effect and safety of physiotherapy with strength training and protein-dense nutritional supplement in combination with anabolic steroids in cross-continuum rehabilitation of patients wi...
    Medical condition: Area of investigation is recovery of muscle strength and function following hip fracture surgery.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004863 10017287 Fractured hip LLT
    20.1 100000004863 10017299 Fractured neck of femur LLT
    20.1 100000004863 10034736 Pertrochanteric fracture of femur, closed LLT
    20.1 100000004863 10053653 Femur fracture subtrochanteric LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Oct 30 16:51:00 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA